摘要
目的明确CD137在北方地区经典型霍奇金淋巴瘤（cHL）中的表达，探讨其作为cHL辅助病理鉴别诊断新指标的可能应用价值。方法收集54例CHL患者资料，以55例伴有“HRS样细胞”的非cHL患者为对照。在病理组织标本中选取“HRS细胞”或“HRS样细胞”丰富的区域制作组织芯片；以“HRS细胞”或“HRS样细胞”为观察对象，cHL组应用CD30、CD15、CD20、PAX5、CD3免疫组织化学染色；同时对两组患者标本进行CD137（BBK-2）抗体免疫组织化学染色及采用EBV编码的小RNA（EBER）原位杂交法检测EBV感染状态。结果54例cHL患者均为淋巴结内原发，中位年龄45．5（22．0～68．0）岁；男女比例1．7：1；对照组患者结内54例，结外（皮肤）1例，中位年龄50．0（12．0～81．0）岁；男女比例1．9：1。54例cHL患者均表达CD30，HRS细胞主要诊断相关免疫标志物CD30、CD15、CD20、CD3阳性表达率依次为100．0％、70．4％、18．5％和0，可见PAX5弱至中等强度表达，阳性率70．4％；EBV感染阳性率25．9％（对照组阳性率21．8％）。cHL组CD137阳性率57．4％，对照组阳性率14．5％，差异有统计学意义（P〈0．001）。将cHL组及对照组按照患者年龄（≥60≤60岁）、性别、有无EBV感染、组织学亚型以及主要诊断相关标志物的表达与否进行分组，CD137阳性率差异均无统计学意义（P值均〉0．05）。以2013年为界进行分组，2013年前后两组cHL患者的CD137阳性率差异有统计学意义（39．4％对85．7％，P=0．001），对照组差异无统计学意义（12．5％对16．1％，P=0．705）；2013以后存档的标本中cHL组与对照组患者CD137阳性率差异有统计学意义（85．7％对16．1％，P〈0．001）。结论通过研究初步证实北方地区大多数cHL患者的HRS细胞表达CD137，而对照组患者“HRS样细胞”CD137阳性率较低。保存期3年以内较保存期3年以上的cHL患者标�
Objective To investigate the expression of CD137 in HRS cells of classical Hodgkin Lymphoma （cHL）, and its application in the pathological differential diagnosis. Methods 54 cases of cHL with ＂HRS＂ cells, and 55 cases of non-cHL with ＂HRS-like＂ cells as control group were collected. ＂HRS＂ cells and ＂HRS-like＂ cells rich areas in slides were selected from relevant groups to produce two tissue microarrays. This study focused solely on ＂HRS＂ cells and ＂HRS-like＂ cells, immunohistochemical staining for antibodies including CD30, CD15, CD20, CD3, and PAX5 were performed on CHL cases, CD137 （clone BBK-2） immunostaining and EBER in situ hybridization were detected in both groups. Results All cHL cases aged 22.0-68.0 （median 45.5） years with the male to female ratio as about 1.7：1 primarily involved lymph nodes; while in the control group, 54 cases aged 12.0-81.0 （median 50.0） years with male： female=l.9：1 primarily located in nodes with only 1 case in skin. In the cHL group, CD30, CD15, CD20 and CD3 were positive in 100.0%, 70.4%, 18.5% and 0 cases in order, and PAX5 showed weak to moderate positive in 70.4% cases; the positive rate of EBER was 25.9% in cHL group, and 21.8% in the control group; The CD137 positive rates were 57.4% in cHL and 14.5% in the control groups with a significant difference （P〈0.001）. There were no significant differences when CD137 expressions were further compared according to the differences in age [elder group （aged 60） / non elderly group], gender （male/female）, EBV infection （yes/no）, histological subtype and the expression of those major diagnostic markers （positive/negative） in either cHL or control groups （all P valued〉0.05）. The positive rates of CD137 expression in cHL were significantly different when sub-grouped according to accession year before or after 2013 （39.4% vs 85.7%, P=0.001 ）; However, no difference was seen in the control group （ 12.5% vs 16.1%, P=0.705）. For those cases after 2013, the CD1
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2016年第6期484-490,共7页
Chinese Journal of Hematology
